These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2006-004956-19||A randomized, open-label, multi-center, phase II/III study on treatment with ABR-217620 combined with IFN-α vs. IFN-α alone in patients with advanced renal cell carcinoma||2013-01-18||due-trials|
|Reported results||2007-003470-26||Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer. Final Protocol dated 2007...||2015-08-18||due-trials|
|Reported results||2009-011245-55||An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE). Final Protocol dated 2009-...||2010-09-10||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2010-021870-12||A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer||2015-08-07||bad-data|
|Reported results||2011-001667-44||An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod)||2013-02-15||due-trials|